Business
Why the Immutep (ASX:IMM) share price is up 6% today
The Immutep Ltd (ASX: IMM) share price is soaring in early-afternoon trade. This comes after the company announced a second clinical trial collaboration with subsidiaries of Merck & Co. (MSD). At the time of writing, the biotechnology company’s shares are up 5.97% to 36 cents.
New Phase 2b trial
The Immutep share price is on the move as investors have been rallying up on the positive news.
According to its release, Immutep advised that it has entered a second clinical trial collaboration and supply agreement with MSD. This will see Immutep commence a new Phase 2b trial, named TACTI-003 using first-line head and neck squamous cell carcinoma (HNSCC) patients.
HNSCC is an aggressive life-threatening cancer that affects either the…
-
Business22 hours agoWhy Auckland Airport, Australian Ethical, Breville, and Clarity shares are charging higher
-
Business24 hours agoMacquarie increases price target for Qantas shares
-
Noosa News24 hours agoHoyts Is Set to Launch Up to Five New IMAX Screens in Australia — Including at Melbourne Central Before the End of 2025
-
Noosa News22 hours agoCommonwealth Bank executive Christopher James McCann found dead in Springbrook National Park